NIAID SBIR-Technology Transfer Direct Phase II (R44)

Post Date

February 17th 2016

Application Due Date

June 23rd 2016

Funding Opportunity Number

RFA-AI-16-009

CFDA Number(s)

93.855
93.856

Funding Instrument Type(s)

Grant

Funding Activity Categories

Health

Eligibility Categories

Small Businesses

Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.

Funding

• Estimated Total Funding:

  $2000000

• Award Range:

  $None - $None

Grant Description

The goal of this Funding Opportunity Announcement (FOA) is to move commercially-viable vaccines and products for treatment and prevention of diseases relevant to NIAID's mission from NIAID intramural research laboratories into the marketplace. This FOA solicits Small Business Innovation Research (SBIR) grant applications from Small Business Concerns (SBCs) for projects that incorporate the appropriate research expertise (company, NIAID Intramural or external collaborators/consortiums) to further develop and commercialize such inventions. The Direct-to-Phase II grant mechanism is intended to facilitate SBIR-type research and development, to expand research and development opportunities for applicant SBCs, and to enhance the pace of technology development and commercialization.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-16-009.html